While SLR-LNPs hold promise as an intralesional therapy, IT administrationmay not be possible or practical for many patients and/or cancer types.31 Therefore, we next focused our investigationson the larger challenge of achieving the safe and effective systemicadministration of RIG-I agonists for cancer immunotherapy. The gene discussed is RIGI; the disease is cancer.